These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23640527)

  • 21. Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
    Levy JH
    Clin Lab Med; 2014 Sep; 34(3):443-52. PubMed ID: 25168936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
    Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
    Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
    Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
    Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
    Spyropoulos AC; Douketis JD; Gerotziafas G; Kaatz S; Ortel TL; Schulman S;
    J Thromb Haemost; 2012 Apr; 10(4):692-4. PubMed ID: 22934291
    [No Abstract]   [Full Text] [Related]  

  • 26. Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
    Lane DA; Wood K
    Circulation; 2015 Apr; 131(16):e412-5. PubMed ID: 25901074
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
    Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical pharmacological aspects of new oral anticoagulants].
    Haschke M
    Ther Umsch; 2012 Nov; 69(11):657-60. PubMed ID: 23117669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
    Kasmeridis C; Lip GY; Apostolakis S
    Hosp Pract (1995); 2013 Feb; 41(1):61-70. PubMed ID: 23466968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New oral anticoagulants after acute coronary syndrome.
    Bennaghmouch N; Ten Berg JM
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):141-50. PubMed ID: 23953902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants.
    Miller MP; Trujillo TC; Nordenholz KE
    Am J Emerg Med; 2014 Apr; 32(4):375-82. PubMed ID: 24512886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bleeding and surgery in the treatment with new oral anticoagulants. The management can be complicated by the lack of specific antidotes].
    Dalén M; Hjemdahl P; Holmström M; Ivert T
    Lakartidningen; 2014 Jun 11-17; 111(24):1064-8. PubMed ID: 25129916
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New anticoagulants--are we prepared?].
    Pawlikowska Z; Szponar J
    Przegl Lek; 2012; 69(8):483-5. PubMed ID: 23243913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The novel anticoagulants: the surgeons' prospective.
    Shamoun FE; Martin EN; Money SR
    Surgery; 2013 Mar; 153(3):303-7. PubMed ID: 23218887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
    Barry M
    Ir Med J; 2013 Mar; 106(3):69. PubMed ID: 23951972
    [No Abstract]   [Full Text] [Related]  

  • 37. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
    Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.
    Gehrie E; Tormey C
    Arch Pathol Lab Med; 2015 May; 139(5):687-92. PubMed ID: 25927153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing new oral anticoagulants in the perioperative and intensive care unit setting.
    Levy JH; Faraoni D; Spring JL; Douketis JD; Samama CM
    Anesthesiology; 2013 Jun; 118(6):1466-74. PubMed ID: 23416382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
    Fenger-Eriksen C; Münster AM; Grove EL
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):651-9. PubMed ID: 24716468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.